New research supports earlier findings that the weight loss drug Belviq (lorcaserin) may play a role in helping delay or manage the progression of type 2 diabetes. In the study, Belviq performed better than a placebo in helping people with prediabetes and diabetes lower their A1C, effectively helping those with prediabetes avoid full-blown diabetes.  Read more